抗生素非劣效试验中风险差置信区间的统计方法差异及其对研究结论的影响
该二次分析纳入213项抗生素非劣效试验的224个比较,用Wald、Agresti-Caffo、Newcombe、Miettinen-Nurminen和SCAS五种方法重算风险差置信区间。多数试验未报告所用统计方法;五种方法的置信区间宽度中位数相近,97.7%的比较非劣效结论一致。在每组样本量≤100且治疗成功率>90%的亚组中,不同方法导致的非劣效结论差异更大。
要点
- 多数抗生素非劣效试验未报告风险差置信区间的统计方法。
- 五种方法计算的置信区间宽度相近,非劣效结论在97.7%的比较中一致。
- 每组样本量≤100且成功率>90%时,不同方法对非劣效结论影响更大。
核心结论
- 不同统计方法计算风险差置信区间在2.3%的比较中导致不同的非劣效结论。
- 置信区间宽度差异在每组样本量≤100且治疗成功率>90%的试验中最大。
研究设计与样本
- 对一项系统评价的二次分析,纳入比较不同抗生素方案、报告主要结局风险差及每组成功和/或失败例数的非劣效试验。
- 共纳入213项研究的224个比较,用Wald、Agresti-Caffo、Newcombe、Miettinen-Nurminen和SCAS五种方法重新计算风险差置信区间。
- 比较不同方法的置信区间宽度和非劣效结论,置信区间越宽视为越保守。
主要发现
- 134个(59.8%)比较未报告计算置信区间所用的统计方法。
- Wald、Agresti-Caffo、Newcombe、Miettinen-Nurminen和SCAS法的置信区间宽度中位数(IQR)分别为13.0%(10.8%, 17.4%)、13.3%(10.9%, 18.5%)、13.6%(11.1%, 18.9%)、13.6%(11.1%, 19.0%)和13.4%(11.1%, 18.9%)。
- 在216个报告非劣效界值的比较中,211个(97.7%)的五种方法非劣效结论相同。
- 在每组样本量≤100且治疗成功率>90%的亚组中,18项指定非劣效界值的试验里,Wald、Agresti-Caffo、Newcombe、Miettinen-Nurminen和SCAS法分别有17项(94.4%)、16项(88.9%)、14项(77.8%)、14项(77.8%)和15项(83.3%)显示非劣效。
关键数值与推荐
- 非劣效结论一致的比较为211/216(97.7%)。
- 置信区间宽度中位数范围13.0%至13.6%。
- 亚组中非劣效显示率范围77.8%至94.4%。
临床怎么用
- 抗生素非劣效试验应明确报告计算风险差置信区间所用的统计方法。
- 在每组样本量≤100且治疗成功率>90%时,需注意统计方法对非劣效结论的潜在影响。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Numerous statistical methods can be used to calculate the confidence interval (CI) of risk differences. There is consensus in previous literature that the Wald method should be discouraged. We compared five statistical methods for estimating the CI of risk difference in terms of CI width and study conclusion in antibiotic non-inferiority trials. METHODS: In a secondary analysis of a systematic review, we included non-inferiority trials that compared different antibiotic regimens, reported risk differences for the primary outcome, and described the number of successes and/or failures as well as patients in each arm. For each study, we re-calculated the risk difference CI using the Wald, Agresti-Caffo, Newcombe, Miettinen-Nurminen, and skewness-corrected asymptotic score (SCAS) methods. The CIs by different statistical methods were compared in terms of CI width and conclusion on non-inferiority. A wider CI was considered to be more conservative. RESULTS: The analysis included 224 comparisons from 213 studies. The statistical method used to calculate CI was not reported in 134 (59.8%) cases. The median (interquartile range IQR) for CI width by Wald, Agresti-Caffo, Newcombe, Miettinen-Nurminen, and SCAS methods was 13.0% (10.8%, 17.4%), 13.3% (10.9%, 18.5%), 13.6% (11.1%, 18.9%), 13.6% (11.1% and 19.0%), and 13.4% (11.1%, 18.9%), respectively. In 216 comparisons that reported a non-inferiority margin, the conclusion on non-inferiority was the same across the five statistical methods in 211 (97.7%) cases. The differences in CI width were more in trials with a sample size of 100 or less in each group and treatment success rate above 90%. Of the 18 trials in this subgroup with a specified non-inferiority margin, non-inferiority was shown in 17 (94.4%), 16 (88.9%), 14 (77.8%), 14 (77.8%), and 15 (83.3%) cases based on CI by Wald, Agresti-Caffo, Newcombe, Miettinen-Nurminen, and SCAS methods, respectively. CONCLUSIONS: The statistical method used to calculate CI was not reported in the majority of antibiotic non-inferiority trials. Different statistical methods for CI resulted in different conclusions on non-inferiority in 2.3% cases. The differences in CI widths were highest in trials with a sample size of 100 or less in each group and a treatment success rate above 90%. TRIAL REGISTRATION: PROSPERO CRD42020165040 . April 28, 2020.
引用
- Bai AD, Komorowski AS, Lo CKL, et al. Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials. Trials. 2021. PMID: 34656155. doi:10.1186/s13063-021-05686-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。